“We had a very successful quarter where we released our first clinical data as a company and extended our cash runway beyond additional Phase 2 clinical readouts,” commented Lawrence Klein, PhD, Chief Executive Officer of Oruka. “We are seeing increased interest in both of our co-lead programs, with additional appreciation that each could become a very impactful medicine in psoriatic disease and beyond. We’re excited by our continued rapid progress advancing both ORKA-001 and -002 and look forward to sharing our first Phase 2 data in 2026.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- ORKA Earnings this Week: How Will it Perform?
- Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know
- Oruka Therapeutics initiated with a Buy at Guggenheim
- Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright
- Oruka Therapeutics initiated with an Overweight at Barclays